ENTITY

CStone Pharmaceuticals (2616 HK)

90

Analysis

Health Care • Hong Kong

CStone Pharmaceuticals operates as a biotechnology company. The Company develops immuno-oncology and molecularly targeted drugs to address unmet medical needs for cancer patients. CStone Pharmaceuticals serves customers worldwide.

more

Refresh

Exchange Announcement • 21 Nov 2024 08:00

Voluntary Announcement - Cstone And Pharmalink Enter Into Strategic Partnership For Sugemalimab In Middle East And North Africa Region And South Africa

Exchange Announcement • 11 Nov 2024 12:00

Voluntary Announcement - Cstone Presents Preclinical Data On Cs2009 At The 2024 Sitc Annual Meeting

Exchange Announcement • 06 Nov 2024 08:00

Voluntary Announcement - Cstone To Present Latest Clinical Data On Cs5001 For Lymphoma At The 66th American Society Of Hematology (Ash) Annual Meeting

Exchange Announcement • 31 Oct 2024 12:00

Voluntary Announcement - Cstone Announces Mhra Approval Of Sugemalimab For First-Line Treatment Of Non-Small Cell Lung Cancer (Nsclc) In The Uk

Exchange Announcement • 28 Oct 2024 12:00

Voluntary Announcement - Cstone Announces Publication Of Population Pharmacokinetics Modelling Of Cejemly (Sugemalimab) In British Journal Of Clinical Pharmacology

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.40.5

x